Company overview
Seer provides the Proteograph product suite, an integrated solution for unbiased deep proteomics analysis using engineered nanoparticles, automation instruments, and software. It enables biomarker discovery, target identification, and multiomics research for cancer, neurodegenerative, and metabolic diseases. Seer partners with service providers worldwide and collaborates with Thermo Fisher Scientific to promote its technology alongside Orbitrap Astral mass spectrometers.
Seer is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include seer proteomics, proteograph suite, deep proteomics, biomarker discovery, multiomics research.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://seer.bio
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- seer proteomics, proteograph suite, deep proteomics, biomarker discovery, multiomics research
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What proteomics capabilities does Seer offer?
- Seer offers the Proteograph suite for deep, unbiased proteomics, including automation instruments, proprietary nanoparticles, and analysis software for biomarker discovery and multiomics in cancer, neurodegeneration, and metabolic diseases.
- What are Seer's key partnerships and integrations?
- Seer has a co-marketing agreement with Thermo Fisher Scientific to pair Proteograph with Orbitrap Astral mass spectrometers and partners with select global service providers to scale proteomics adoption.
- What applications does Seer's technology support?
- Applications include target identification, biomarker discovery for complex diseases, and complementing genomics data in pharma, biotech, academic labs, and CROs.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
